Abstract
Blockade of the renin-angiotensin system reduces cardiovascular morbidity and mortality in diabetic patients. Angiotensin II (Ang II) plays an important role in the structural and functional abnormalities of the diabetic heart. We investigated whether or not Ang II type 1 receptor blocker (ARB) could attenuate left ventricular (LV) remodeling in male mice with diabetes mellitus (DM) induced by the injection of streptozotocin (200 mg/kg, i.p.). Diabetic mice were treated with candesartan (1 mg/kg/day; DM+Candesartan, n=7) or vehicle (DM+Vehicle, n=7) for 8 weeks. Heart rate and aortic blood pressure were comparable between the groups. Normal systolic function was preserved in diabetic mice. In contrast, diastolic function was impaired in DM+Vehicle and was improved in DM+Candesartan, as assessed by the deceleration time of the peak velocity of transmitral diastolic flow (40.3±0.3 vs. 37.3±0.5 ms, p<0.01) and the time needed for relaxation of 50% maximal LV pressure to baseline value (τ; 10.6±0.7 vs. 8.7±0.6 ms, p<0.05) without significant changes in heart rate and aortic blood pressure. Improvement of LV diastolic function was accompanied by the attenuation of myocyte hypertrophy, interstitial fibrosis and apoptosis in association with the expression of connective tissue growth factor (CTGF) and myocardial oxidative stress. Moreover, candesartan directly inhibited Ang II–mediated induction of CTGF in cultured cardiac fibroblasts. ARB might be beneficial to prevent cardiac abnormalities in DM.
Similar content being viewed by others
Article PDF
References
Beckman JA, Creager MA, Libby P : Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–2581.
Mizushige K, Yao L, Noma T, et al: Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899–907.
Fiordaliso F, Li B, Latini R, et al: Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000; 80: 513–527.
Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II–mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11–34.
Way KJ, Isshiki K, Suzuma K, et al: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709–2718.
Matsushima S, Kinugawa S, Ide T, et al: Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006; 291: H2237–H2245.
Matsushima S, Ide T, Yamato M, et al: Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2006; 113: 1779–1786.
Knollmann BC, Blatt SA, Horton K, et al: Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem 2001; 276: 10039–10048.
Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM : Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993; 72: 1245–1254.
Fiordaliso F, Leri A, Cesselli D, et al: Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001; 50: 2363–2375.
Young ME, McNulty P, Taegtmeyer H : Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105: 1861–1870.
Shiomi T, Tsutsui H, Ikeuchi M, et al: Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003; 42: 165–172.
Riva E, Andreoni G, Bianchi R, et al: Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res 1998; 37: 233–240.
Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S : Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest 1990; 86: 481–488.
Norton GR, Candy G, Woodiwiss AJ : Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996; 93: 1905–1912.
Yamamoto K, Masuyama T, Sakata Y, et al: Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55: 76–82.
Mezzano SA, Ruiz-Ortega M, Egido J : Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635–638.
Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A : Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a type II diabetic rat model. Diabetologia 2002; 45: 402–415.
Twigg SM, Cao Z, SV MC, et al: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002; 143: 4907–4915.
Grotendorst GR, Okochi H, Hayashi N : A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469–480.
Gore-Hyer E, Shegogue D, Markiewicz M, et al: TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002; 283: F707–F716.
Liu BC, Chen Q, Luo DD, et al: Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003; 24: 67–73.
Yu J, Prado GN, Taylor L, et al: Global chimeric exchanges within the intracellular face of the bradykinin B2 receptor with corresponding angiotensin II type Ia receptor regions: generation of fully functional hybrids showing characteristic signaling of the AT1a receptor. J Cell Biochem 2002; 85: 809–819.
Iwanciw D, Rehm M, Porst M, Goppelt-Struebe M : Induction of connective tissue growth factor by angiotensin II: integration of signaling pathways. Arterioscler Thromb Vasc Biol 2003; 23: 1782–1787.
Ricupero DA, Romero JR, Rishikof DC, Goldstein RH : Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 2000; 275: 12475–12480.
Williams B : Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001; 87: 10C–17C.
Hayashidani S, Tsutsui H, Ikeuchi M, et al: Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285: H1229–H1235.
Matsusaka H, Ide T, Matsushima S, et al: Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 2006; 47: 711–717.
Weber KT : Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96: 4065–4082.
Kakkar R, Kalra J, Mantha SV, Prasad K : Lipid peroxidation and activity of antioxidant enzymes in diabetic rats. Mol Cell Biochem 1995; 151: 113–119.
Kanazawa A, Nishio Y, Kashiwagi A, Inagaki H, Kikkawa R, Horiike K : Reduced activity of mtTFA decreases the transcription in mitochondria isolated from diabetic rat heart. Am J Physiol Endocrinol Metab 2002; 282: E778–E785.
Fiordaliso F, Bianchi R, Staszewsky L, et al: Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004; 37: 959–968.
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.
Lang D, Mosfer SI, Shakesby A, Donaldson F, Lewis MJ : Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II. Circ Res 2000; 86: 463–469.
Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G : Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999; 100: 292–298.
Okada K, Hirano T, Ran J, Adachi M : Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27: 293–299.
Investigators HOPEHS, Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin-converting–enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
Vasan RS, Benjamin EJ, Levy D : Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565–1574.
Jessup M, Brozena S : Heart failure. N Engl J Med 2003; 348: 2007–2018.
Hunt SA, Abraham WT, Chin MH, et al: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154–e235.
Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
Shiomi T, Tsutsui H, Hayashidani S, et al: Pioglitazone, a peroxisome proliferator–activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126–3132.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsutsui, H., Matsushima, S., Kinugawa, S. et al. Angiotensin II Type 1 Receptor Blocker Attenuates Myocardial Remodeling and Preserves Diastolic Function in Diabetic Heart. Hypertens Res 30, 439–449 (2007). https://doi.org/10.1291/hypres.30.439
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.439
Keywords
This article is cited by
-
Angiotensin II blockers improve cardiac coronary flow under hemodynamic pressure overload
Hypertension Research (2021)
-
Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice
Cardiovascular Diabetology (2015)
-
DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats
Diabetology & Metabolic Syndrome (2015)
-
Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2014)
-
Myofibroblast-mediated mechanisms of pathological remodelling of the heart
Nature Reviews Cardiology (2013)